DPP-4 inhibitors in diabetic patients with chronic kidney disease and end-stage kidney disease on dialysis in clinical practice

Contributions to Nephrology

Volumn 185, Issue , 2015, Pages 98-115

  Abe, Masanori ^a   Okada, Kazuyoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; GLYCOSYLATED SERUM ALBUMIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SERUM ALBUMIN;

COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHY; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE, CHRONIC; METABOLISM; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SERUM ALBUMIN;

EID: 84930162156     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000380974     Document Type: Article

References (44)

1. Abe M, Okada K, Soma M: Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011; 12: 57-69
2. Deacon CF, Mannucci E, Ahren B: Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab 2012; 14: 762-767
3. Kim YG, Hahn S, Oh TJ, et al: Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013; 56: 696-708
4. Levey AS, de Jong PE, Coresh J, et al: The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17-28
5. Jafar TH, Stark PC, Schmid CH, et al: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition, a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252
6. Slinin Y, Ishani A, Rector T, et al: Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. Am J Kidney Dis 2012; 60: 747-769
7. Bonds DE, Miller ME, Bergenstal RM, et al: The association between symptomatic, severe hypoglycemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340:b4909
8. Patel A, MacMahon S, Chalmers J, et al: Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
9. Duckworth W, Abraira C, Moritz T, et al: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139
10. Davis TME: Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. Diabetes Obes Metab 2014; 16: 891-899
11. Chan JCN, Scott R, Ferreria JCA, et al: Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008; 10: 545-555
12. Ferreira JCA, Marre M, Barzilai N, et al: efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2013; 36: 1067-1073
13. Hattori S: Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 2011; 58: 69-73
14. Nowicki M, Rychlik I, Haller H, et al: Saxagliptin improves glycemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011; 13: 523-532
15. Nowicki M, Rychlik I, Haller H, et al: Longterm treatment with the dipeptidyl peptidase-inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomized controlled 52-week efficacy and safety study. Int J Clin Pract 2011; 65: 1230-1239
16. Lukashevich V, Schweizer A, Shao Q, et al: Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011; 13: 947-954
17. Kothny W, Shao Q, Groop PH, et al: One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate to severe renal impairment. Diabetes Obes Metab 2012; 14: 1032-1039
18. Tani S, Nagao K, Hirayama A: Association between urinary albumin excretion and lowdensity lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study. Am J Cardiovasc Drugs 2013; 13: 443-450
19. Fujita H, Taniai H, Murayama H, et al: DPP-inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1 in type 2 diabetic patients with incipient nephropathy. Endocr J 2014; 61: 159-166
20. Sakai Y, Suzuki A,Mugishima K, et al: Effects of alogliptin in chronic kidney disease patients with type 2 diabetes. Intern Med 2014; 53: 195-203
21. Ohashi N, Tsuji N, Naito Y, et al: Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels. Med Sci Monit 2014; 20: 587-593
22. Groop PH, Cooper ME, Perkovic V, et al: Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 disbetes and renal dysfunction. Diabetes Care 2013; 36: 3460-3468
23. Groop PH, Prato SD, Taskinen MR, et al: Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab 2014; 16: 560-568
24. McGill JB, Sloan L, Newman J, et al: Longterm efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, doubleblind, placebo-controlled study. Diabetes Care 2013; 36: 237-244
25. Karagiannis T, Paschos P, Paletas K, et al: Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344:e1369
26. White WB, Cannon CP, Heller SR, et al: Alogliptin after acute coronary syndrome in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1327-1335
27. Scirica BM, Bhatt DL, Braunwald E, et al: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326
28. Scheen AJ: Cardiovascular effects of gliptins. Nat Rev Cardiol 2013; 10: 73-84
29. Schernthaner G, Ritz E, Schernthaner GH: Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly? Nephrol Dial Transplant 2010; 25: 2044-2047
30. Inaba M, Okuno S, Kumeda Y, et al: Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18: 896-903
31. Abe M, Matsumoto K: Glycated hemoglobin or glycated albumin for assessment of glycemic control in dialysis patients with diabetes? Nat Clin Pract Nephrol 2008; 4: 482-483
32. Okada T, Nakao T, Matsumoto H, et al: Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med 2007; 46: 807-814
33. Inaba M, Maekawa K, Okuno S, et al: Impact of atherosclerosis on the relationship of glycemic control and mortality in diabetic patients on hemodialysis. Clin Nephrol 2012; 78: 273-280
34. Isshiki K, Nishio T, Isono M, et al: Glycated albumin predicts the risk of mortality in type 2 diabetic patients on hemodialysis: evaluation of a target level for improving survival. Ther Apher Dial 2014; 18: 434-442
35. The Japanese Society for Dialysis Therapy: Guidelines. 2012. http://www.jsdt.or.jp/jsdt/1637.html (accessed January 26, 2015)
36. Abe M, Okada K, Ikeda K, et al: Characterization of insulin adsorption behavior of dialyzer membranes used in hemodialysis. Artif Organs 2011; 35: 398-403
37. Abe M, Kaizu K, Matsumoto K: Evaluation of the hemodialysis-induced changes in plasma glucose and insulin concentrations in diabetic patients: comparison between the hemodialysis and non-hemodialysis days. Ther Apher Dial 2007; 11: 288-295
38. Ferreira JCA, Corry D, Mogensen CE, et al: Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 2013; 61: 579-587
39. Ito M, Abe M, Okada K, et al: The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 2011; 58: 979-987
40. Kume S, Uzu T, Takagi C, et al: Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis. J Diabetes Invest 2012; 3: 298-301
41. Nakamura Y, Inagaki M, Shimizu T, et al: Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study. Nephron Clin Pract 2013; 123: 46-51
42. Fujii Y, Abe M, Higuchi T, et al: The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother 2013; 14: 259-267
43. Nakamura Y, Tsuji M, Hasegawa H, et al: Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes. Hemodial Int 2014; 18: 433-442
44. Otsuki H, Kosaka T, Nakamura K, et al: Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type2 diabetes. Int Urol Nephrol 2014; 46: 427-432.